Residential substance user treatment programs as venues for HCV pharmacological treatment: Client and staff perspectives

Substance Use and Misuse

Volumn 40, Issue 12, 2005, Pages 1811-1829

  Strauss, Shiela M ^a,c   Astone, Janetta M ^a   Munoz Plaza, Corrine ^a   Hagan, Holly ^a,d   Des Jarlais, Don ^a,b,e  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c Statistics and Data Analysis Core   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Drug users; HCV medication; Hepatitis C; Residential substance user treatment

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; FATIGUE; FEMALE; GUILT; HAIR LOSS; HEADACHE; HEALTH PROGRAM; HEPATITIS C; HUMAN; MALE; MOOD DISORDER; NAUSEA; PAIN; PRIORITY JOURNAL; RESIDENTIAL CARE; SHAME; SIDE EFFECT; SUBSTANCE ABUSE; SUPPORT GROUP;

ADULT; ANTIVIRAL AGENTS; COMMUNICATION; FEMALE; HEALTH PERSONNEL; HEALTH PROMOTION; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROFESSIONAL-PATIENT RELATIONS; RESIDENTIAL TREATMENT; SUBSTANCE-RELATED DISORDERS;

EID: 27544440150     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826080500261097     Document Type: Article

References (45)

1. Alter, M. J., Moyer, L. A. (1998). The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(Suppl 1):S6-S10.
2. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., Margolis, H. S. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341(8):556-562.
3. Backmund, M., Meyer, K., Von Zielonka, M., Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology 34(1):188-193.
4. Barabási, A. -L. (2002). Linked: The New Science of Networks. Cambridge, MA: Perseus.
5. Bride, B. E., Real, E. (2003). Project Assist: a modified therapeutic community for homeless women living with HIV/AIDS and chemical dependency. Health Soc. Work 28(2):166-168.
6. Broers, B., Morabia, A., Hirschel, B. (1994). A cohort study of drug users' compliance with zidovudine treatment. Arch. Intern. Med. 154(10):1121-1127.
7. Centers for Disease Control and Prevention. (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 47(RR-19):1-39.
8. Chander, G., Sulkowski, M. S., Jenckes, M. W., Torbenson, M. S., Herlong, H. F., Bass, E. B., Gebo, K. A. (2002). Treatment of chronic hepatitis C: a systematic review. Hepatology 36(5 Suppl 1):S135-S144.
9. Chitwood, D. D., McBride, D. C., French, M. T., Comerford, M. (1999). Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Subst. Use Misuse 34(4&5):727-746.
10. Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., Peters, M. G., Koziel, M. J., Bhan, A. K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C., AIDS Clinical Trials Group A5071 Study Team. (2004). Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5):451-459.
11. Conway, B., Prasad, J., Reynolds, R., Farley, J., Jones, M., Jutha, S., Smith, N., Mead, A., DeVlaming, S. (2004). Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin. Infect. Dis. 38(Suppl. 5):S402-S408.
12. Edlin, B. R., Seal, K. H., Lorvick, J., Kral, A. H., Ciccarone, D. H., Moore, L. D., Lo, B. (2001). Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N. Engl. J. Med. 345(3):211-215.
13. Feuer, A. (2004). Hepatitis C outbreak adds a new woe to drug centers. N.Y. Times, 17 July.
14. Hagan, H., Thiede, H., Weiss, N. S., Hopkins, S. G., Duchin, J. S., Alexander, E. R. (2001). Sharing of drug preparation equipment associated with hepatitis C virus seroconversion in drug injectors. Am. J. Public Health 91(1):42-46.
15. Hoofnagle, J. H. (2002). Course and outcome of hepatitis C. Hepatology 36(5 Suppl 1):S21-S29.
16. Kahneman, D., Tversky, A., Slovic, P. (1982). Judgment Under Uncertainty: Heuristics and Biases. Cambridge, UK: Cambridge University Press.
17. Kalichman, S. C., Sikkema, K. J., Somlai, A. (1996). People living with HIV infection who attend and do not attend support groups: a pilot study of needs, characteristics and experiences. AIDS Care 8(5):589-599.
18. King, V. L., Brooner, R. K. (1999). Assessment and treatment of comorbid psychiatric disorders. In: Strain, E.C.; Sitzer, M.L., eds. Methadone Treatment for Opiate Dependence. Baltimore: Johns Hopkins University Press, pp. 141-165.
19. Kraus, M. R., Schafer, A., Faller, H., Csef, H., Scheurlen, M. (2003). Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J. Clin. Psychiatry 64(6):708-714.
20. Liang, T. J., Rehermann, B., Seeff, L. B., Hoofnagle, J. H. (2000). Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132(4):296-305.
21. Lorvick, J., Kral, A. H., Seal, K., Gee, L., Edlin, B. R. (2001). Prevalence and duration of hepatitis C among injection drug users in San Francisco, California. Am. J. Public Health 91(1):46-47.
22. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M., Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958-965.
23. Mauss, S., Berger, F., Goelz, J., Jacob, B., Schmutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40(1):120-124.
24. McCoy, H. V., Messiah, S. E., Zhao, W. (2002). Improving access to primary health care for chronic drug users: an innovative systemic intervention for providers. J. Behav. Health Serv. Res. 29(4):445-457.
25. McLellan, A. T., Hagan, T. A., Levine, M., Gould, F, Meyers, K., Bencivengo, M., Durell, J. (1998). Supplemental social services improve outcomes in public addiction treatment. Addiction 93(10):1489-1499.
26. Mochida, S., Ohnishi, K., Matsuo, S., Kakihara, K., Fujiwara, K. (1996). Effect of alcohol intake on the efficacy of Interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin. Exp. Res. 20(9 Suppl):371A-377A.
27. National Institutes of Health. (2002). Management of Hepatitis C: 2002. NIH Consensus Statement, 19(1). Available at: http://consensus.nih.gov/cons/116/ 116cdc_intro.htm (accessed November 22, 2004).
28. Nyamathi, A., Leake, B., Keenan, C., Gelberg, L. (2000). Type of social support among homeless women: its impact on psychosocial resources, health and health behaviors, and use of health services. Nurs. Res. 49(6):318-326.
29. O'Dell, K. J., Turner, N. H., Weaver, G. D. (1998). Women in recovery from drug misuse: an exploratory study of their social networks and social support. Subst. Use Misuse 33(8):1721-1734.
30. Patton, M. Q. (1990). Qualitative Evaluation and Research Methods. Newbury Park, CA: Sage Publications.
31. Pole, C. J., Lampard, R. (2002). Practical Social investigation: Qualitative and Quantitative Methods in Social Research. Englewood Cliffs, NJ: Prentice Hall.
32. Poynard, T., Bedossa, P., Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832.
33. Rutschmann, O.T., Negro, F., Hirschel, B., Hadengue, A., Anwar, D., Perrin, L. H. (1998). Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J. Infect Dis. 177(3):783-785.
34. Samet, J. H., Libman, H., Steger, K. A., Dhawan, R. K., Chen, J., Shevitz, A. H., Dewees-Dunk, R., Levenson, S., Kufe, D., Craven, D. E. (1992). Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am. J. Med. 92(5):495-502.
35. Selwyn, P. A., Budner, N. S., Wasserman, W. C., Arno, P. S. (1993). Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 108(4):492-500.
36. Summers, J., Robinson, R., Capps, L., Zisook, S., Atkinson, J. H., McCutchan, E., McCutchan, J. A., Deutsch, R., Patterson, T., Grant, I. (2000). The influence of HIV-related support groups on survival in women who lived with HIV. A pilot study. Psychosomatics 41(3):262-268.
37. Sylvestre, D. L. (2002). Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug AlcoholDepend. 67(2):117-123.
38. Tortu, S., Neaigus, A., McMahon, J., Hagen, D. (2001). Hepatitis C among non-injecting drug users: a report. Subst. Use Misuse 36(4):523-534.
39. Tortu, S., McMahon, J. M., Pouget, E. R., Hamid, R. (2004). Sharing of non-injection drug-use implements as a risk factor for hepatitis C. Subst. Use Misuse 39(2):211-224.
40. Tuan, Y.-F. (1974). Topophilia: A Study of Environmental Perception, Attitudes and Values. Englewood Cliffs, New Jersey: Prentice Hall.
41. Tucker, J. S., Orlando, M., Burnam, M. A., Sherbourne, C. D., Kung, F. Y., Gifford, A. L. (2004). Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychol. 23(4):363-370.
42. Umbricht-Schneiter, A., Ginn, D. H., Pabst, K. M., Bigelow, E. (1994). Providing medical care to methadone clinic patients: referral vs on-site care. Am. J. Public Health 84(2):207-210.
43. Ware, J. E. Jr., Bayliss, M. S., Mannocchia, M., Davis, G. L. (1999). Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 30(2):550-555.
44. Williams, I. (1999). Epidemiology of hepatitis C in the United States. Am. J. Med. 107(6B):2S-9S.
45. Witteveen, E., van Ameijden, E. J. (2002). Drug users and HIV-combination therapy (HAART): factors which impede or facilitate adherence. Subst. Use Misuse 37(14):1905-1925.